Genflow Biosciences (LON:GENF) Advancements in SIRT6 Variant Patent Application

Genflow Biosciences Advances SIRT6 Variant Patent Application Following Positive Search Report from European Patent Office

Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce today that its exclusive, out-licensed patent application for “Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases” has successfully progressed through the Supplementary European Search Report without further questions from the European Patent Office (EPO).

The European patent application (EP 22 808 414.1), originally filed on May 13, 2022, by the University of Rochester, The Trustees of Columbia University in the City of New York, and the Albert Einstein College of Medicine, marks a significant step in securing protection for SIRT6 variants, a promising innovation in age-related disease therapeutics. The SIRT6 gene/protein, is known for its critical role in DNA repair, metabolism, and longevity.

Following the EPO’s assessment, no further questions were raised, allowing the application to progress to the national phase of the patent process, a critical stage in securing market-specific protections across Europe.

Key Details:

·    Application Title: Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases

·    Applicants: University of Rochester; The Trustees of Columbia University in the City of New York; Albert Einstein College of Medicine

·    Patent Application Number: EP 22 808 414.1

·    Filing Date: 13 May 2022

·    Result: The application met all requirements of the European Patent Convention (EPC).

·    Next Steps: Genflow is preparing its intention to advance the application required by 7 July 2025.

Genflow remains focused on advancing its longevity-focused therapeutic pipeline and will continue to update stakeholders as the patent application progresses.

Dr. Eric Leire, CEO of Genflow commented: “This positive outcome represents a significant step forward in securing broad intellectual property protection for our innovative work on SIRT6 variants. This milestone strengthens our position in SIRT6-based therapeutics and accelerates our mission to develop effective treatments for age-related diseases.”

Contacts